Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: An eastern cooperative ontology group phase II study (E2E93)

Cancer Journal

Volumn 7, Issue 2, 2001, Pages 155-164

  Schink, J C ^a   Weller, E ^a   Harris, L S ^a   Cella, D ^a   Gerstner, J ^a   Falkson, C ^a   Wadler, S ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; SOUTH AFRICA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0035045119     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chemotherapy in ovarian carcinoma: Present roles and future prospects
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Preliminary report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV suboptimal ovarian cancer
4. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials
5. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
6. Taxol in relapsed ovarian cancer: High v low dose and short v long infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group
7. Carboplatin and paclitaxel in patients with advanced ovarian cancer, a dose finding study
8. Quality of life end points in cancer clinical trials: Review and recommendations
9. Creatinine clearance: Bedside estimate
10. Carboplatin dosage: Prospective evaluation ora simple formula based on renal function
11. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
12. Non-parametric estimation from incomplete observations
13. Quality of life as a new end point
14. Report from a National Cancer Institute workshop on quality of life assessment in cancer clinical trials
15. Quality of life in clinical cancer trials: Experience and perspective of the European Organization for Research and Treatment of Cancer
16. Quality of life of women with ovarian cancer
17. Trial-related quality of life: Using quality-of-life assessment to distinguish among cancer therapies
18. Quality of life in long-term cancer survivors